ETI60

Overview

ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.68 μM) and TLR9 ( IC 50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI60 can be used for autoimmune and inflammatory diseases research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > ERK | Products > Signaling Pathways > JNK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TNF Receptor

Product Information

• Catalog No.: HY-178169
• CAS No.: 2773475-11-7
• Molecular Formula: C21H28N4O
• Molecular Weight: 352.47
• Purity: 99.51%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
• Availability: In-stock

Source

Original product source